Search This Blog

Thursday, December 12, 2019

Grifols launches subcutaneously administered immunoglobulin

Grifols S.A. (OTCPK:GIKLY) launches Xembify (immune globulin subcutaneous human-klhw), its first 20% subcutaneous immunoglobulin therapy for the treatment of patients at least two-year-olds with primary immunodeficiency.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)